| Description |
1 online resource (xv, 433 pages) |
| Series |
CTAR ; v. 157 |
|
C.T.A.R. ; v. 157 |
|
Cancer treatment and research ; v. 157
|
| Contents |
Introduction to the hematopoietic growth factors -- Early-acting hematopoietic growth factors: biology and clinical experience -- Granulocyte colony-stimulating factors -- Erythropoiesis-stimulating agents -- Thrombopoietin factors -- Cyclic and chronic neutropenia -- The myeloid growth factors -- Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy -- Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy -- Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome -- Do erythropoietic-stimulating agents relieve fatigue?: a review of reviews -- Randomized controlled trials of the erythroid-stimulating agents in cancer patients -- Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients -- Clinical practice guidelines for the use of erythroid-stimulating agents: ASCO, EORTC, NCCN -- Thrombocytopenia and platelet transfusions in patients with cancer -- Romiplostim -- Eltrombopag -- The hematopoietic growth factors in acute leukemia: US perspective -- The hematopoietic growth factors in acute leukemia: a European perspective -- The hematopoietic growth factors in the myelodysplastic syndromes -- Hematopoietic growth factors in older cancer patients -- The economics of the hematopoietic growth factors |
| Summary |
No area of cancer supportive care better illustrates the advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of hematopoietic growth factors. Myelosuppressive agents, with their potential hematopoietic toxicities, remain the mainstay of systemic treatment for both metastatic and early stage cancer. Hematopoietic Growth Factors in Oncology reviews and integrates the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents, each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. "Hematopoietic growth factors have revolutionized the treatment of patients with a spectrum of cancers and benign bone marrow disorders. This text addresses the mechanism of action and clinical impact of these cytokines. Leading investigators in the field provide and update of current state of knowledge and future challenges."--Steven T. Rosen, M.D. Series Editor |
| Bibliography |
Includes bibliographical references and index |
| Notes |
English |
|
Print version record |
| Subject |
Hematopoietic growth factors.
|
|
Oncology.
|
|
Neoplasms -- drug therapy
|
|
Medical Oncology
|
|
Colony-Stimulating Factors -- pharmacology
|
|
Colony-Stimulating Factors -- therapeutic use
|
|
HEALTH & FITNESS -- Diseases -- Cancer.
|
|
MEDICAL -- Oncology.
|
|
Médecine.
|
|
Hematopoietic growth factors
|
|
Oncology
|
| Form |
Electronic book
|
| Author |
Lyman, Gary H. (Gary Herbert), 1946-
|
|
Dale, David C.
|
| ISBN |
9781441970732 |
|
1441970738 |
|
1282971867 |
|
9781282971868 |
|
9786612971860 |
|
661297186X |
|
